SEARCH

SEARCH BY CITATION

References

  • 1
    Wilson W, Gharavi A, Koike T, Lockshin M, Branch W, Piette J, Brey R, Derksen R, Harris E, Hughes G, Triplett D, Khamashta M. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of and International workshop. Arthritis Rheum 1999; 42: 130911.
  • 2
    Love PE, Santoro SA. Antiphospholipid antibodies. anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 68298.
  • 3
    Pierangeli SS, Harris EN. In vivo models of thrombosis for the antiphospholipid syndrome. Lupus 1996; 5: 4515.
  • 4
    Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 21120.
  • 5
    Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmun 2000; 15: 16372.
  • 6
    Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti β2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997; 78: 100814.
  • 7
    Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Kitani T, Iwatani Y, Kanakura Y. Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001; 114: 64754.
  • 8
    Cabiedes J, Cabral AR, Alarcón-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899906.
  • 9
    Guerin J, Feighery C, Sim RB, Jackson J. Antibodies to β2-glycoprotein I − a specific marker for the antiphospholipid syndrome. Clin Exp Immunol 1997; 109: 3049.
  • 10
    Carreras LO, Forastiero RR. Pathogenic role of antiprotein-phospholipid antibodies. Haemostasis 1996; 26: 34057.
  • 11
    Roubey RAS. Tissue factor pathway and the antiphospholipid syndrome. J Autoimmun 2000; 15: 21720.
  • 12
    Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 27681.
  • 13
    Adams MJ, Donohoe S, Mackie IJ, Machin SJ. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. Br J Haematol 2001; 114: 3759.
  • 14
    Salemink I, Blezer R, Willems GM, Galli M, Bevers E, Lindhout T. Antibodies to β2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 2000; 84: 6536.
  • 15
    Cakir B, Arnett FC, Roubey RAS. Autoantibodies to tissue factor pathway inhibitor (TFPI) are associated with arterial thrombosis/stroke. J Autoimmun 2000; 15: A11(Abstract).
  • 16
    Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 903.
  • 17
    Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 95972.
  • 18
    Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 269505.
  • 19
    Brandt JT. Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant: an update. Thromb Haemost 1995; 74: 118590.
  • 20
    Broze GJ Jr, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994; 5: 5519.
  • 21
    Willems GM, Janssen MP, Salemink I, Wun TC, Lindhout T. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipids membranes. Biochemistry 1998; 37: 33218.
  • 22
    Adams MJ, Oostryck R. Further investigations of lupus anticoagulant interference in a functional assay for tissue factor pathway inhibitor. Thromb Res 1997; 87: 2459.
  • 23
    Jacobsen EM, Sandset PM, Wisloff F. Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor? Thromb Res 1999; 94: 21320.
  • 24
    Forastiero RR, Martinuzzo ME, Carreras LO. Binding properties of antibodies to prothrombin and β2-glycoprotein I assayed by ELISA and Dot blot. Clin Exp Immunol 1999; 118: 4806.
  • 25
    Tincani A, Spatola L, Prati E, Allegri F, Ferremi P, Cattaneo R, Meroni P, Balestrieri G. The anti-β2 glycoprotein I activity in human anti-phospholipid syndrome is due to monoreactive low-affinity autoantibodies directed to epitopes located on native β2 glycoprotein I and preserved during species' evolution. J Immunol 1996; 157: 57328.
  • 26
    Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 11205.
  • 27
    Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2002; 22: 53948.
  • 28
    Kazama, Y. The importance of the binding of factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor. the transmembrane and cytoplasmic domains of tissue factor are not essential for the inhibitory reaction of tissue factor pathway inhibitor. Thromb Haemost 1997; 77: 4927.